NEJM Journal Watch Diabetes for April 16, 2024

NEJM Journal Watch | Diabetes

View in browser

April 16, 2024 Gustavo Braslavsky

This is a free email alert. To experience NEJM Journal Watch in full, please subscribe.

SUMMARY AND COMMENT   Semaglutide Improves Outcomes in Patients with Obesity, HFpEF, and Type 2 Diabetes Karol E. Watson, MD, PhD, FACC, reviewing Kosiborod MN et al. N Engl J Med 2024 Apr 6 In a randomized, controlled trial, semaglutide resulted in greater weight loss, improved symptoms, and fewer serious adverse events compared with placebo.

MORE IN DIABETES »

NEJM CareerCenter Jobs Endocrinology - Chief of Endocrinology - Sayre, PA Endocrinology Sayre, Pennsylvania Endocrinologist Endocrinology Somerville, Massachusetts Endocrinologist Endocrinology Ogden, Utah Division Chief, Endocrinology Chiefs / Directors / Dept. Heads, Endocrinology Somerville, Massachusetts

nejmcareercenter.org

	SPECIAL OFFER
	Subscribe to NEJM Journal Watch General Medicine
	NEJM Journal Watch General Medicine is a clinician's first source for summaries of the latest research and guidelines that affect patient care. Stay clinically prepared and foster professional development with a subscription today. For the latest medical research developments in a clinically relevant context Subscribe today.

FOLLOW US

This email was sent to gustavo.braslavsky@gmail.com. To unsubscribe from this alert or update your preferences, go to My Alerts. Did this NEJM Journal Watch alert get forwarded to you? Sign up here. To ensure a consistent delivery of NEJM Journal Watch emails, please add diabetes@j.jwatch.org to your contacts or address book. NEJM Journal Watch 860 Winter Street Waltham, MA 02451 USA Copyright © 2024 Massachusetts Medical Society. All rights reserved.